查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1498418

全球过敏性结膜炎市场：依疾病类型、药物类别、通路、国家及公司分析（2024-2032）

Global Allergic Conjunctivitis Market Report by Disease Type (Seasonal ALLERGIC Conjunctivitis, Perennial Allergic Conjunctivitis ), Drug class, Distribution Channel, Countries and Company Analysis, 2024-2032
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球过敏性结膜炎市场规模预计将从2023年的19.6亿美元增加到2032年的24亿美元，2024年至2032年复合年增长率为2.27%。

过敏性结膜炎也可互换称为眼睛过敏 (OA)。过敏性结膜炎是一种常见的免疫超敏反应，影响许多人。近年来，过敏性结膜炎的发生率呈上升趋势，搔痒、红肿等症状在全球普遍存在，极大地影响了人们的生活品质。此外，过敏性结膜炎是一种经常未被充分诊断和治疗的健康问题。这是因为很少有患者因过敏性结膜炎症状而就医，大多数患者接受非处方药治疗，而不辅以药物治疗。

结膜炎通常可以自我诊断，几乎不需要进行诊断测试。因此，过敏性结膜炎的流动预计将有助于预测期内的市场成长。根据NIH 2021 年2 月发表的另一篇论文，病毒和细菌性结膜炎是感染性结膜炎的两种常见形式，病毒感染占急性结膜炎病例的80%，而细菌感染占病例的50-75 %。据同一消息来源称，在中国等国家，结膜炎的盛行率也很高。此外，根据BMC 2022年3月发表的论文，中国大陆出血性结膜炎的年平均发生率为3.58/10万人。出血性结膜炎盛行率的增加预计将推动结膜炎治疗的需求并促进市场成长。

全球过敏性结膜炎患者数量的增加和医疗服务需求的增加预计将成为市场成长的主要动力。此外，随着患者数量的不断增加，许多主要市场公司都专注于过敏性结膜炎治疗药物的研发活动，这也促进了过敏性结膜炎市场的成长。

根据 2022 年 4 月《Nature》杂誌发表的一篇论文，大约 10% 的样本人群患有过敏性结膜炎。在印度，5-15岁族群过敏性结膜炎的盛行率为12.22%。此外，2021 年 1 月发表的 NCBI 论文指出，超过一半的患者报告他们的日常症状是季节性或常年性的，大约 75% 的人认为他们的症状很严重。此外，在欧洲，每10,000人中有1.2至10.6人患有春季角结膜炎。过敏性结膜炎的流动预计将推动对有效治疗的需求，并有助于研究领域的成长。

此外，增加接触污染物和化学物质也是过敏性结膜炎的原因，预计将推动过敏性结膜炎市场的预测。然而，过敏性结膜炎治疗药物的副作用可能会阻碍市场成长。相反，人们对这种疾病的认识不断提高，为大公司投资过敏性结膜炎市场创造了机会。

北美过敏性结膜炎市场

由于有效治疗方法的可用性和消费者对结膜炎的高度认识等因素，预计北美将主导市场。根据 2020 年 2 月发表的一篇National Library Medicine论文，结膜炎每年影响美国超过 600 万人。据估计，这种疾病每年造成的损失约为 3.77 亿美元至 8.57 亿美元。结膜炎是该国最常见的疾病，影响15%至40%的人口，并且在春季和夏季更为常见。

此外，2021 年 1 月发表的 NCBI 论文指出，季节性或常年性过敏性结膜炎是最常见的过敏性结膜炎类型，占美国眼部过敏的 95% 以上。它影响男性和女性，影响 15% 至 40% 的人口。美国的这种结膜炎流行预计将推动对有效治疗的需求，并在预测期内促进市场成长。

由于其广泛的医疗服务和大量的结膜炎患者，预计该市场很快就会在美国占据最大占有率。此外，预计加拿大结膜炎的高盛行率将有助于预测期内的市场成长。BMC 2022 年 10 月发表的一篇论文估计，21% 的加拿大人患有干眼症。结膜炎的流动预计将促进加拿大市场的成长。

该报告研究了全球过敏性结膜炎市场，并提供了市场动态、区域和细分市场分析以及主要参与者的收入分析。

目录

第1章 简介

第2章 研究方法

第3章 执行摘要

第4章 市场动态

  • 增长动力
  • 任务

第5章 全球过敏性结膜炎市场

第6章 全球过敏性结膜炎市占率分析

  • 依疾病类型
  • 依药物类别
  • 依分销渠道
  • 依国家

第7章 疾病类型

  • 季节性过敏性结膜炎（SAC）
  • 常年性过敏性结膜炎（PAC）

第8章 药物类别

  • 抗组织胺/肥大细胞稳定药
  • 皮质类固醇
  • 其他

第9章 分销通路

  • 医院药房
  • 网上药店
  • 零售药局/药局
  • 其他

第10章 国家

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 比利时
    • 荷兰
    • 土耳其
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 韩国
    • 泰国
    • 马来西亚
    • 印度尼西亚
    • 纽西兰
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国

第11章波特五力分析

第12章 SWOT分析

第十三章主要公司分析

  • Ajanta Pharma Limited
  • Alembic Pharmaceutical Ltd.
  • Cipla Inc.
  • Indoco Remedies Ltd.
  • Johnson & Johnson
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
简介目录

Allergic Conjunctivitis Market is expected to reach US$ 2.40 Billion by 2032 from US$ 1.96 Billion in 2023, with a CAGR of 2.27% during 2024-2032.

Allergic conjunctivitis interchangeably is also known as Ocular allergy (OA). It is a common immunological hypersensitivity disorder affecting numerous populations. In recent years, allergic conjunctivitis has been increasing in frequency, with symptoms of itching, redness, and swelling globally that significantly impact an individual's quality of life. Besides, allergic conjunctivitis is an often under diagnosed and undertreated health problem because very few patients with allergic conjunctivitis symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary no pharmacological remedies.

Generally, conjunctivitis is self-diagnosable, and there is the least need to undergo any diagnostic test for this disease. Thus, the incidence of allergic conjunctivitis is expected to contribute to the market's growth during the forecast period. As per another NIH article published in February 2021, viral and bacterial conjunctivitis are the two common forms of infectious conjunctivitis, with viral infection responsible for up to 80% of all acute conjunctivitis cases and bacterial infection accounting for between 50-75% of cases of infectious conjunctivitis in children. According to the same source, countries like China also have a high incidence of conjunctivitis. Moreover, as per the BMC article published in March 2022, the average annual hemorrhagic conjunctivitis incidence was 3.58/100,000 in mainland China. The rising incidence of hemorrhagic conjunctivitis is expected to drive the demand for conjunctivitis treatment, thereby contributing to market growth.

Increase in patient population of allergic conjunctivitis worldwide and escalating demand for healthcare services is expected to majorly drive the market growth. In addition, many key market players are focusing on R&D activities to develop drugs for allergic conjunctivitis as patient population is increasing, which also drives the allergic conjunctivitis market growth.

As per the Nature article published in April 2022, approximately 10% of the sample population had allergic conjunctivitis. In India, the prevalence of allergic conjunctivitis was 12.22% among those aged between five and 15 years. Also, the NCBI article published in January 2021 mentioned that more than half of the patients report daily symptoms as seasonal or perennial and around 75% consider their symptoms to be severe. The same source also mentioned that there were between 1.2 and 10.6 cases of vernal keratoconjunctivitis per 10,000 individuals in Europe. Such incidence of allergic conjunctivitis is expected to drive the demand for effective treatment, contributing to the growth of the studied segment.

Furthermore, rise in exposure to pollutants and chemicals causes allergic conjunctivitis and is also expected to propel the allergic conjunctivitis market forecast. However, adverse reaction of allergic conjunctivitis medications can impede the growth of the market. Conversely, increase in awareness about the disease creates allergic conjunctivitis market opportunity for the key players to invest.

North America allergic conjunctivitis market

North America is expected to dominate the market, owing to factors such as the easy availability of effective treatment products and high awareness among consumers regarding conjunctivitis in the region. As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.

Also, the NCBI article published in January 2021 mentioned that seasonal or perennial allergic conjunctivitis is the most prevalent form of allergic conjunctivitis, with more than 95% of ocular allergy cases in the United States. It is observed in both sexes and affects between 15% and 40% of the population. Such prevalence of conjunctivitis in the United States is expected to drive the demand for effective treatment, thereby contributing to the market's growth during the forecast period.

Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share shortly. Also, the high prevalence of conjunctivitis in Canada is expected to contribute to the market's growth over the forecast period. As per the BMC article published in October 2022, it is estimated that 21% of Canadians have dry eyes. Such prevalence of conjunctivitis is expected to contribute to market growth in Canada.

Allergic Conjunctivitis Industry Analysis

The Allergic conjunctivitis competitive landscape includes an analysis of global and local companies which hold market shares and are well known, including Ajanta Pharma Limited, Akorn Operating Company LLC, Alembic Pharmaceutical Ltd., Cipla Inc., Indoco Remedies Ltd., Johnson & Johnson, Novartis AG, Ocular Therapeutix, Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Disease Types - Global Allergic Conjunctivitis Market is divided into 2 viewpoints

1. Seasonal ALLERGIC Conjunctivitis (SAC)

2. Perennial Allergic Conjunctivitis (PAC)

Drugs Class - Global Allergic Conjunctivitis Market is divided into 3 viewpoints

1. Antihistamines & Mast Cell Stabilizers

2. Corticosteroids

3. Others

Distribution Channels - Global Allergic Conjunctivitis Market is divided into 4 viewpoints

1. Hospital Pharmacies

2. Online Pharmacies

3. Retail Pharmacies & Drug Stores

4. Others

Countries - Market is divided into 25 country Allergic Conjunctivitis Industry

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. Australia

5. South Korea

6. Thailand

7. Malaysia

8. Indonesia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. South Africa

2. Saudi Arabia

3. United Arab Emirates

Company Insights:

1. Overview

2. Operating business segments

3. Product portfolio & Product Launch in Last 1 Year

4. Recent Developments

5. Revenue

Companies Covered:

1. Ajanta Pharma Limited

2. Akorn Operating Company LLC

3. Alembic Pharmaceutical Ltd.

4. Cipla Inc.

5. Indoco Remedies Ltd.

6. Johnson & Johnson

7. Novartis AG

8. Ocular Therapeutix, Inc.

9. Sun Pharmaceutical Industries Ltd.

10. Teva Pharmaceutical Industries Ltd.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Allergic Conjunctivitis Market

6. Global Allergic Conjunctivitis Market Share Analysis

  • 6.1 By Disease Types
  • 6.2 By Drugs Class
  • 6.3 By Distribution Channels
  • 6.4 By Country

7. Disease Types

  • 7.1 Seasonal ALLERGIC Conjunctivitis (SAC)
  • 7.2 Perennial Allergic Conjunctivitis (PAC)

8. Drugs Class

  • 8.1 Antihistamines & Mast Cell Stabilizers
  • 8.2 Corticosteroids
  • 8.3 Others

9. Distribution Channels

  • 9.1 Hospital Pharmacies
  • 9.2 Online Pharmacies
  • 9.3 Retail Pharmacies & Drug Stores
  • 9.4 Others

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 South Korea
    • 10.3.6 Thailand
    • 10.3.7 Malaysia
    • 10.3.8 Indonesia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 South Africa
    • 10.5.2 Saudi Arabia
    • 10.5.3 United Arab Emirates

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Competition
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threats

13. Key Players Analysis

  • 13.1 Ajanta Pharma Limited
    • 13.1.1 Overview
    • 13.1.2 Operating business segments
    • 13.1.3 Product portfolio & Product Launch in Last 1 Year
    • 13.1.4 Recent Developments
    • 13.1.5 Revenue
  • 13.2 Akorn Operating Company LLC
    • 13.2.1 Overview
    • 13.2.2 Operating business segments
    • 13.2.3 Product portfolio & Product Launch in Last 1 Year
    • 13.2.4 Recent Developments
    • 13.2.5 Revenue
  • 13.3 Alembic Pharmaceutical Ltd.
    • 13.3.1 Overview
    • 13.3.2 Operating business segments
    • 13.3.3 Product portfolio & Product Launch in Last 1 Year
    • 13.3.4 Recent Developments
    • 13.3.5 Revenue
  • 13.4 Cipla Inc.
    • 13.4.1 Overview
    • 13.4.2 Operating business segments
    • 13.4.3 Product portfolio & Product Launch in Last 1 Year
    • 13.4.4 Recent Developments
    • 13.4.5 Revenue
  • 13.5 Indoco Remedies Ltd.
    • 13.5.1 Overview
    • 13.5.2 Operating business segments
    • 13.5.3 Product portfolio & Product Launch in Last 1 Year
    • 13.5.4 Recent Developments
    • 13.5.5 Revenue
  • 13.6 Johnson & Johnson
    • 13.6.1 Overview
    • 13.6.2 Operating business segments
    • 13.6.3 Product portfolio & Product Launch in Last 1 Year
    • 13.6.4 Recent Developments
    • 13.6.5 Revenue
  • 13.7 Novartis AG
    • 13.7.1 Overview
    • 13.7.2 Operating business segments
    • 13.7.3 Product portfolio & Product Launch in Last 1 Year
    • 13.7.4 Recent Developments
    • 13.7.5 Revenue
  • 13.8 Ocular Therapeutix, Inc.
    • 13.8.1 Overview
    • 13.8.2 Operating business segments
    • 13.8.3 Product portfolio & Product Launch in Last 1 Year
    • 13.8.4 Recent Developments
    • 13.8.5 Revenue
  • 13.9 Sun Pharmaceutical Industries Ltd.
    • 13.9.1 Overview
    • 13.9.2 Operating business segments
    • 13.9.3 Product portfolio & Product Launch in Last 1 Year
    • 13.9.4 Recent Developments
    • 13.9.5 Revenue
  • 13.10 Teva Pharmaceutical Industries Ltd.
    • 13.10.1 Overview
    • 13.10.2 Operating business segments
    • 13.10.3 Product portfolio & Product Launch in Last 1 Year
    • 13.10.4 Recent Developments
    • 13.10.5 Revenue